Pivotal AUR87A study of GAGome-based liquid biopsy for kidney cancer recurrence opens 26th site
Stockholm, Dec 15, 2021: Swedish molecular diagnostics company Elypta announces today the activation of the 26th recruiting site for the AURORAX-0087A (AUR87A) study, making it the largest diagnostics study ever of the most common type of kidney cancer. AUR87A is intended to validate Elypta’s metabolism-based liquid biopsy platform for the detection of recurrence after surgery in clear cell renal cell carcinoma (ccRCC).About 1 in 5 ccRCC patients experience recurrence within 5 years after surgery for confirmed disease. Since there is no liquid biomarker yet approved for ccRCC recurrence,